Navigation Links
Maxygen Announces Hold on MAXY-alpha Development Program
Date:9/21/2007

REDWOOD CITY, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Roche has advised Maxygen, Inc. (Nasdaq: MAXY) that it has voluntarily placed a hold on further clinical development of MAXY-alpha, also known as R7025. MAXY-alpha is a novel interferon-alpha for the treatment of Hepatitis C and Hepatitis B virus infections and is licensed to Roche.

Preliminary observations from a Phase I trial indicate that an unexpected reduction of the pharmacodynamic and pharmacokinetic effects of MAXY-alpha occurred in the majority of subjects who received two doses of MAXY-alpha. In addition, antibodies binding to MAXY-alpha were identified in some subjects. Roche has initiated additional investigational studies in order to assess these results.

"We are all surprised by these unexpected findings," said Russell Howard, Maxygen's chief executive officer. "We don't yet know how this will impact the future timing or advancement of the program. Roche has now started additional work to assess the meaning and significance of these results. We will provide an update once all relevant information is collected and evaluated."

About the Maxygen and Roche Agreement

Maxygen and Roche entered into an agreement in 2003 to develop novel interferon alpha and beta products for a wide range of indications. Roche licensed from Maxygen worldwide commercialization rights to specific novel interferon product candidates for the treatment of Hepatitis C and B virus infections. Maxygen received an initial payment, full research and development funding for work done by Maxygen in the first two years of the collaboration, and milestone payments for the advancement of the MAXY-alpha product candidate. In addition, Maxygen is eligible to receive
'/>"/>

SOURCE Maxygen, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. (NASDAQ: ... is striving to become a leader in the development ... announced that the final CVac data from the Phase ... clear trend for a clinically meaningful improvement in Overall ... remission patients. In the group of second ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Dec. 29, 2010 Reportlinker.com announces that ... in its catalogue: Molecular Diagnostics Markets ... The technologies that constitute molecular ... situ hybridization (FISH), second-generation biochips and microfluidics, ...
... DIEGO, Dec. 28, 2010 Cardium Therapeutics (NYSE Amex: ... the Company,s Matrix Phase 2b clinical study has been ... and Regeneration and provided an update on plans ... dressing.   (Logo:   http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO ) ...
... 2010 An international team of researchers featuring Texas ... that gives a new spin to semiconductor nanoelectronics and ... developed an electrically controllable device whose functionality is based ... a 20-year scientific quest involving many international researchers and ...
Cached Biology Technology:Reportlinker Adds Molecular Diagnostics Markets 2Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans 2Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans 3Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans 4Texas A&M professor helps develop first high-temp spin-field-effect transistor 2Texas A&M professor helps develop first high-temp spin-field-effect transistor 3
(Date:5/10/2015)... May 11, 2015 Fingerprint Cards (FPC) ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... used by smartphone manufacturers in China . ... communicated revenue guidance of + 1 000 MSEK for 2015.   ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/21/2015)... -- High crime rate, increasing government ... control systems market in Saudi Arabia ... report by TechSci Research " Saudi Arabia Access Control Systems Market ... market in Saudi Arabia is ... systems market in the Kingdom is growing at a ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... 21, 2013 Reportlinker.com announces that a ... its catalogue: Global ... This report analyzes the ... Thousands by the following Product Segments: Automated ...
... important step in the ongoing battle against secondhand tobacco smoke. ... can immediately detect the presence of secondhand smoke and even ... and about the size of a matchbox car, the device ... air. A sensor chip then records the data on an ...
... world,s fastest-growing Open Access publishers and among the largest ... a new journal, Frontiers in Public Health . ... high quality, rigorously peer-reviewed articles on the most outstanding ... of Public Health. On the Frontiers interactive web ...
Cached Biology News:Global Fingerprint Biometrics Industry 2Global Fingerprint Biometrics Industry 3Global Fingerprint Biometrics Industry 4Global Fingerprint Biometrics Industry 5Global Fingerprint Biometrics Industry 6Global Fingerprint Biometrics Industry 7Global Fingerprint Biometrics Industry 8Global Fingerprint Biometrics Industry 9Global Fingerprint Biometrics Industry 10Global Fingerprint Biometrics Industry 11Global Fingerprint Biometrics Industry 12Global Fingerprint Biometrics Industry 13Global Fingerprint Biometrics Industry 14Global Fingerprint Biometrics Industry 15Global Fingerprint Biometrics Industry 16Global Fingerprint Biometrics Industry 17Global Fingerprint Biometrics Industry 18Global Fingerprint Biometrics Industry 19Scientists create new tools for battling secondhand smoke 2Scientists create new tools for battling secondhand smoke 3Frontiers announces launch of new open-access journal, Frontiers in Public Health 2
... Insect Cells are derived from the Spodoptera frugiperda ... growth, use in transfections, plaque assays, virus production, ... a protocol that optimizes recovery of viable cells ... serum-free BacVector Insect Cell Medium and can also ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
... The Dyad Disciple thermal cycler is ... It may also be operated independently, using ... variety of interchangeable Alpha units (sample-holder, heat-pump ... well as the Chromo4 real-time detector. Peltier ...
...
Biology Products: